Theravance Biopharma (TBPH) Operating Leases (2019 - 2026)

Theravance Biopharma (TBPH) has 8 years of Operating Leases data on file, last reported at $29.8 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 20.34% year-over-year to $29.8 million in Q1 2026; TTM through Mar 2026 was $29.8 million, a 20.34% decrease from a year earlier, with the FY2025 full-year figure at $31.8 million, down 18.79% from the prior year.
• Operating Leases for Q1 2026 stood at $29.8 million, down from $31.8 million in the prior quarter.
• Over the last five years, Operating Leases for TBPH reached as high as $51.4 million in Q3 2022 and fell as low as $29.8 million in Q1 2026.
• Historically, Operating Leases has averaged $41.3 million across 5 years, with a median of $42.4 million in 2024.
• Across the five-year window, Operating Leases increased 0.18% in 2024 and slipped 20.34% in 2026, its largest moves.
• Year by year, Operating Leases stood at $45.4 million in 2022, then declined by 0.38% to $45.2 million in 2023, then retreated by 13.55% to $39.1 million in 2024, then fell by 18.79% to $31.8 million in 2025, then decreased by 6.32% to $29.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $29.8 million in Q1 2026, $31.8 million in Q4 2025, and $33.7 million in Q3 2025.